Literature DB >> 10226741

Hematopoietic growth factor levels in term and preterm infants.

G Rondini1, G Chirico.   

Abstract

The problems of immunologic adaptation during the transitional period from intra- to extrauterine life are responsible for the physiologic immaturity of the immune function in newborn infants. In preterm neonates the immunodeficiency is more severe and prolonged and is associated with a higher incidence of infections and sepsis. Furthermore, due to immaturity of the hematologic system, anemia, thrombocytopenia, and neutropenia are frequently observed in very low birth weight infants. The dysregulation of cytokine and hematopoietic growth factor synthesis is an important contributory factor to the complex deficiency of immunologic and hematologic function in the neonate and may explain the reduced incidence of acute graft-versus-host disease observed after cord blood transplantation in children. Human milk is a rich source of most of the cytokines that are reduced in the neonate. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and erythropoietin are currently under evaluation in newborn infants with septic neutropenia or anemia of prematurity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226741     DOI: 10.1097/00062752-199905000-00011

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  2 in total

1.  More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Josephine McAuliffe; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

2.  The role of granulocyte colony-stimulating factor in the neutrophilia observed in the fetal inflammatory response syndrome.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Stanley M Berry; Sonia S Hassan; Bo Hyun Yoon; Samuel Edwin; Moshe Mazor
Journal:  J Perinat Med       Date:  2011-07-30       Impact factor: 1.901

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.